Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type5 [3 d7 l* ]( K) S
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
7 u$ ^$ m" A& k# f3 Y, {9 c* X+ Author Affiliations
, T9 @) c% E3 }% p! M+ `4 v/ }0 o& ^2 A# l8 b8 [( j, E
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , o, m8 F6 b# B1 W; s8 e
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
S1 N. m e: ?5 c8 s; u+ R. n3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan O2 c# O- |0 Y% `' D1 O3 p1 K
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 7 h& m( r( w' D# `+ y0 ]9 e
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
8 o/ N% G2 R# ^1 M3 x6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan - {0 F; s' g' k. q2 u1 x8 f
7Kinki University School of Medicine, Osaka 589-8511, Japan , ?& O( s K, H* |5 J( ~8 _
8Izumi Municipal Hospital, Osaka 594-0071, Japan
/ Q3 G8 p& {- K0 A5 V9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 H% B* l% C M1 @
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ' P% w+ u8 c2 n( f+ n+ I, S
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
- M* Q* G; z$ [" b
- u3 d; E% R0 \- t: L1 s |